Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer

References

• Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–43
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 2000; 88: 921–32
   PubMed Web of Science ®Google Scholar
• Greenlee, RT, Hill-Harmon, MB, Murray, T, Thun, M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15–36. Erratum in CA Cancer J Clin 2001;51:144.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163–8
   PubMed Web of Science ®Google Scholar
• Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993; 19: 29–44
   PubMed Web of Science ®Google Scholar
• Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005; 10(Suppl 3)49–58
   PubMed Web of Science ®Google Scholar
• Lokich JJ, Ahlgren JD, Gullo JJ, Phillips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425–32
   PubMed Web of Science ®Google Scholar
• Poorter RL, Lauw FN, Bemelman WA, Bakker PJ, Taat CW, Veenhof CH. Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy. Eur J Cancer 1996; 32A: 2262–6
   PubMedGoogle Scholar
• Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22: 333–8
   PubMed Web of Science ®Google Scholar
• Kim YH, Cheong SK, Lee JD, Park JS, Shin SW, Kim JS. Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma. Am J Clin Oncol 1996; 19: 212–6
   PubMed Web of Science ®Google Scholar
• Ravaud A, Borner M, Schellens JH, et al. UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer. Oncology (Williston Park) 1999; 13(7 Suppl 3): 61–3
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16
   PubMed Web of Science ®Google Scholar
• Wadler S, Benson AB, Engelkin C, et al. Recommended guidelines for treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998; 16: 3169–78
   PubMed Web of Science ®Google Scholar
• Woo IS, Moon do H, Shim BY, et al. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. Jpn J Clin Oncol 2005; 35: 13–7
   PubMed Web of Science ®Google Scholar
• Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346–53
   PubMedGoogle Scholar
• Jeen YT, Yoon SY, Shin SW, et al. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer 2001; 91: 2288–93
   PubMed Web of Science ®Google Scholar
• Kim YH, Kim BS, Seo JH, et al. Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma. Oncology (Williston Park) 1999; 13(7 Suppl. 3): 64–8
   Google Scholar
• Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261–7
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996–2004
   PubMed Web of Science ®Google Scholar
• Kang, Y-K, Kim, T-W, Chang, H-M, et al. A phase I/II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer. Proc Am Soc Clin Oncol 2004;22:329s, (Abstract No. 4066).
   Google Scholar
• Elsaid, AA, Elkerm, Y. Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. Proc Am Soc Clin Oncol 2005;23:311s, (Abstract No. 4014).
   PubMedGoogle Scholar
• Dupont, J, Jensen, HA, Jensen, BV, Pfeiffer, P. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer. Acta Oncol, (in press).
   Google Scholar
• Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349–58
   PubMed Web of Science ®Google Scholar
• Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17: 239–45
   PubMed Web of Science ®Google Scholar
• Lee CR, Nicholson PW, Souhami RL, Slevin ML, Hall MR, Deshmukh AA. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 1993; 67: 630–4
   PubMed Web of Science ®Google Scholar
• Lee CR, Nicholson PW, Ledermann JA, Rustin GJ. Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol 1996; 17: 99–103
   PubMedGoogle Scholar